☆ 4.4 Article

Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice

THORACIC CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer A retrospective observational study

Hajime Oi et al.

Summary: Weekly nab-PTX and PTX have similar efficacy and safety profiles for relapsed SCLC. In this retrospective study, there were no significant differences in response rate, median progression-free survival, and overall survival between the two treatment options.

MEDICINE (2022)

Add to Collection

Article Oncology

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Ying Cheng et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

MC1923 phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive-stage small cell lung cancer previously treated with chemotherapy and immunotherapy.

Konstantinos Leventakos et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Small-cell lung cancer

Charles M. Rudin et al.

Summary: Small-cell lung cancer is a type of lung cancer characterized by high proliferative rate, early metastasis, and poor prognosis, strongly associated with tobacco carcinogens. Most patients are diagnosed with metastatic disease, with only a small fraction having potentially curative earlier-stage disease. Genomic profiling reveals extensive chromosomal rearrangements and high mutation burden in SCLC, often involving inactivation of TP53 and RB1 tumor suppressor genes.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

D. R. Spigel et al.

Summary: Nivolumab did not show survival benefit compared to chemotherapy in relapsed SCLC, but there is a potential survival benefit in certain baseline characteristics.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Small Cell Lung Cancer, Version 2.2022

Apar Kishor P. Ganti et al.

Summary: The NCCN Clinical Practice Guidelines in Oncology provide recommendations for the management of SCLC, emphasizing the importance of systemic therapy for extensive-stage disease and promoting smoking cessation in patients.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Yun Fan et al.

Summary: The study demonstrated potential antitumor activity of camrelizumab plus apatinib in patients with ED-SCLC who had failed platinum-based chemotherapy, including those who were chemotherapy-sensitive and chemotherapy-resistant. Treatment-related adverse events of grade 3 or higher were reported in a significant proportion of patients, leading to treatment discontinuation in some cases. Further clinical studies are warranted to explore the efficacy of this combination therapy in SCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Oncology

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

A. Ortega-Franco et al.

Summary: SCLC is an aggressive disease with poor prognosis, and platinum/etoposide chemotherapy remains the most effective regimen. The addition of immune checkpoint inhibitors has shown promising results in improving survival, but further research is needed to identify predictive biomarkers for patient selection.

ESMO OPEN (2021)

Add to Collection

Article Respiratory System

Recent developments in the treatment of small cell lung cancer

Birgitta Hiddinga et al.

Summary: Small cell lung cancer (SCLC) is an aggressive disease with a poor prognosis, and chemotherapy remains the mainstay of treatment. Recent advances in staging, surgery, radiotherapy, and systemic treatment have been made, but new treatment options are urgently needed. Immunotherapy and targeted therapy offer hope for improved prognoses in the future, as genomic sequencing reveals new possible targets for treatment.

EUROPEAN RESPIRATORY REVIEW (2021)

Add to Collection

Article Oncology

Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience

Yuchao Wang et al.

Summary: Nanoparticle albumin bound paclitaxel (Nab-P) showed good efficacy and safety as a third-line treatment for relapsed small cell lung cancer (SCLC), with an objective response rate of 24.32% and disease control rate of 81.08%. The main adverse reactions were gastrointestinal reactions, bone marrow suppression, and fatigue.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)

Add to Collection

Article Oncology

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Neal E. Ready et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Review Oncology

Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review

Makoto Nakao et al.

ANTICANCER RESEARCH (2020)

Add to Collection

Article Oncology

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

Francesco Gelsomino et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Editorial Material Oncology

Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression

Thomas E. Stinchcombe et al.

CLINICAL LUNG CANCER (2020)

Add to Collection

Article Oncology

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

Jose Trigo et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer

Xiangwei Ge et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Neal Ready et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Oncology

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

T. K. Owonikoko et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Progress in research on paclitaxel and tumor immunotherapy

Linyan Zhu et al.

CELLULAR & MOLECULAR BIOLOGY LETTERS (2019)

Add to Collection

Review Oncology

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

Yaru Tian et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

Add to Collection

Article Oncology

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer

Yu-Jung Kim et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

David R. Gandara et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer A retrospective analysis

Yujiro Naito et al.

MEDICINE (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.